Collaborators
Partnering
Ducentis is working with world class contract research organizations in order to rapidly develop a portfolio of CD200 variant molecules with a data package supporting efficacy and safety in pre-clinical models.
|
We are working with Prosarix on developing in silico models of CD200 variants and using these models to design CD200 variants with improved pharmacology and pharmaceutical properties.
|
|
We are working with Syngene on characterisation of CD200 mutants in cell free assays.
|
|
We are working with GVK on cloning, expression, purification and stability studies with CD200 mutants.
|
|
We are working with KWS to characterise CD200 variants in in vitro assays using primary human immune cells and rodent models of autoimmunity and inflammatory disease.
|
Partners
Ducentis is open to partnering the CD200 program with pharma or biotech companies seeking to invest in novel biologic therapies for autoimmune disease.